PE20030433A1 - Formulacion liquida que comprende cetuximab - Google Patents
Formulacion liquida que comprende cetuximabInfo
- Publication number
- PE20030433A1 PE20030433A1 PE2002000618A PE2002000618A PE20030433A1 PE 20030433 A1 PE20030433 A1 PE 20030433A1 PE 2002000618 A PE2002000618 A PE 2002000618A PE 2002000618 A PE2002000618 A PE 2002000618A PE 20030433 A1 PE20030433 A1 PE 20030433A1
- Authority
- PE
- Peru
- Prior art keywords
- liquid formulation
- polyoxyethylene
- formulation including
- including cetuximab
- cetuximab
- Prior art date
Links
- 229960005395 cetuximab Drugs 0.000 title abstract 2
- 239000012669 liquid formulation Substances 0.000 title 1
- -1 POLYOXYETHYLENE Polymers 0.000 abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE: a) EL ANTICUERPO MONOCLONAL QUIMERICO C225 ( CETUXIMAB ) CONTRA EL RECEPTOR DEL FACTOR DE CRECIMIENTO ENDOTELIAL (RECEPTOR EGF) ; b) DE 2mM A 100 mM DE UN BUFFER FOSFATO Y c) DE 0,005% A 0,1% DE UN ESTER DE ACIDO GRASO DE POLIOXIETILEN SORBITAN SELECCIONADO DE MONOOLEATO DE POLIOXIETILEN (20) SORBITAN O MONOLAURATO DE POLIOXIETILEN (20) SORBITAN. LA FORMULACION TIENE UN pH ENTRE 6,5 A 7,5 Y CONTIENE ADEMAS UN AGENTE ISOTONICO TAL COMO CLORURO DE SODIO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10133394A DE10133394A1 (de) | 2001-07-13 | 2001-07-13 | Flüssige Formulierung enthaltend Cetuximab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030433A1 true PE20030433A1 (es) | 2003-05-24 |
Family
ID=7691220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000618A PE20030433A1 (es) | 2001-07-13 | 2002-07-11 | Formulacion liquida que comprende cetuximab |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040170632A1 (es) |
| EP (1) | EP1406658A1 (es) |
| JP (1) | JP2004536129A (es) |
| KR (1) | KR20040018458A (es) |
| CN (1) | CN1231264C (es) |
| AR (1) | AR039358A1 (es) |
| BR (1) | BR0211060A (es) |
| CA (1) | CA2453342A1 (es) |
| CZ (1) | CZ2004189A3 (es) |
| DE (1) | DE10133394A1 (es) |
| HU (1) | HUP0401046A3 (es) |
| MX (1) | MXPA04000340A (es) |
| PE (1) | PE20030433A1 (es) |
| PL (1) | PL364599A1 (es) |
| RU (1) | RU2004102395A (es) |
| SK (1) | SK862004A3 (es) |
| WO (1) | WO2003007988A1 (es) |
| ZA (1) | ZA200401161B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4728948B2 (ja) | 2003-02-10 | 2011-07-20 | エラン ファーマシューティカルズ，インコーポレイテッド | 免疫グロブリン製剤およびその調製の方法 |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| BRPI0507608A (pt) * | 2004-02-12 | 2007-07-03 | Merck Patent Gmbh | formulações de anticorpos anti-egfr lìquidas altamente concentradas |
| US20070207149A1 (en) * | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| JP2008519757A (ja) * | 2004-11-12 | 2008-06-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗ｅｇｆｒ抗体の固形物 |
| SI1859793T1 (sl) * | 2005-02-28 | 2011-08-31 | Eisai R&D Man Co Ltd | Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka |
| CN101415422B (zh) | 2006-02-09 | 2012-11-07 | 第一三共株式会社 | 抗癌药用组合物 |
| JP2009535372A (ja) | 2006-05-03 | 2009-10-01 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ |
| CL2007002880A1 (es) * | 2006-10-06 | 2008-05-09 | Amgen Inc | Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d |
| EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| EP3811962A4 (en) | 2018-06-25 | 2022-03-16 | JCR Pharmaceuticals Co., Ltd. | Protein-containing aqueous liquid formulation |
| US20210290644A1 (en) * | 2018-08-31 | 2021-09-23 | Amplyx Pharmaceuticals, Inc. | Compounds and methods for treating fungal infections |
| WO2025113442A1 (zh) * | 2023-11-29 | 2025-06-05 | 四川科伦博泰生物医药股份有限公司 | 抗体制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| AU6267896A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| NZ500539A (en) * | 1995-07-27 | 2001-11-30 | Genentech Inc | An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer |
-
2001
- 2001-07-13 DE DE10133394A patent/DE10133394A1/de not_active Withdrawn
-
2002
- 2002-06-18 CZ CZ2004189A patent/CZ2004189A3/cs unknown
- 2002-06-18 CN CNB028141059A patent/CN1231264C/zh not_active Expired - Fee Related
- 2002-06-18 US US10/483,404 patent/US20040170632A1/en not_active Abandoned
- 2002-06-18 MX MXPA04000340A patent/MXPA04000340A/es unknown
- 2002-06-18 SK SK86-2004A patent/SK862004A3/sk not_active Application Discontinuation
- 2002-06-18 EP EP02751038A patent/EP1406658A1/de not_active Withdrawn
- 2002-06-18 PL PL02364599A patent/PL364599A1/xx unknown
- 2002-06-18 KR KR10-2004-7000530A patent/KR20040018458A/ko not_active Withdrawn
- 2002-06-18 JP JP2003513593A patent/JP2004536129A/ja not_active Withdrawn
- 2002-06-18 RU RU2004102395/15A patent/RU2004102395A/ru not_active Application Discontinuation
- 2002-06-18 BR BR0211060-1A patent/BR0211060A/pt not_active IP Right Cessation
- 2002-06-18 WO PCT/EP2002/006696 patent/WO2003007988A1/de not_active Ceased
- 2002-06-18 CA CA002453342A patent/CA2453342A1/en not_active Abandoned
- 2002-06-18 HU HU0401046A patent/HUP0401046A3/hu unknown
- 2002-07-11 PE PE2002000618A patent/PE20030433A1/es not_active Application Discontinuation
- 2002-07-12 AR ARP020102605A patent/AR039358A1/es unknown
-
2004
- 2004-02-12 ZA ZA200401161A patent/ZA200401161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK862004A3 (en) | 2004-07-07 |
| CA2453342A1 (en) | 2003-01-30 |
| ZA200401161B (en) | 2004-10-22 |
| EP1406658A1 (de) | 2004-04-14 |
| JP2004536129A (ja) | 2004-12-02 |
| US20040170632A1 (en) | 2004-09-02 |
| KR20040018458A (ko) | 2004-03-03 |
| HUP0401046A3 (en) | 2006-11-28 |
| WO2003007988A1 (de) | 2003-01-30 |
| DE10133394A1 (de) | 2003-01-30 |
| RU2004102395A (ru) | 2005-05-27 |
| PL364599A1 (en) | 2004-12-13 |
| BR0211060A (pt) | 2004-07-20 |
| HUP0401046A2 (en) | 2006-04-28 |
| AR039358A1 (es) | 2005-02-16 |
| CZ2004189A3 (cs) | 2004-05-12 |
| CN1527724A (zh) | 2004-09-08 |
| CN1231264C (zh) | 2005-12-14 |
| MXPA04000340A (es) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030433A1 (es) | Formulacion liquida que comprende cetuximab | |
| SA521430342B1 (ar) | تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري | |
| AU3438900A (en) | Use of trehalose for stabilising a liquid vaccine | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| DE69734605D1 (de) | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| MXPA02011303A (es) | Nueva composicion farmaceutica. | |
| JO2481B1 (en) | Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods | |
| IL153406A0 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
| CL2011001406A1 (es) | “formulación farmacéutica líquida estable que comprende un anticuerpo para il-1beta (acz885), manitol, tampón de histidina y polisorbato 80, con un ph entre 5,5-7,0”. | |
| ES2161210T3 (es) | Composiciones anti-patogenamente eficaces que comprenden peptidos liticos y enzimas hidroliticas. | |
| SG150550A1 (en) | Pharmaceutical preparation containing an antibody for the egf receptor | |
| MX275023B (es) | Champu que contiene una red de gel. | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| IL155935A0 (en) | A method of sterilizing a pharmaceutical composition | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| ES2182255T3 (es) | Agente de blanqueo fluorescente. | |
| EA200400259A1 (ru) | Дезинфицирующий раствор на основе гипохлорита натрия и способ его получения | |
| DE60336509D1 (de) | Zubereitungen enthaltend sincalide | |
| BR0304218A (pt) | ésteres alicìclicos com fragrância de almìscar | |
| YU65503A (sh) | Agrohemijske formulacije | |
| PE20230116A1 (es) | Formulacion de anticuerpos | |
| AU2020235128A8 (en) | Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent | |
| CL2004000496A1 (es) | Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |